merck glp-1 moves into obesity with deal for Hansoh's pill Merck & Co. signs license

In a study of diabetic patients, exenatide was found to transiently suppress the expression of inflammatory markers TNF and IL-1

These cases demonstrate the utility of GLP-1 agonists in treating dermatologic conditions that are refractory to other therapies and further highlight the potential of GLP-1 agonists in treating skin disease

Among patients with OSA, initiation rates increased from 16% to 21% within a single quarter, outpacing growth among commercially insured patients

T., Heslinga, M

Its why the article bluntly states, "were not amphibians we dont absorb vitamins through our skin" its true for complex peptides too

Lifestyle elements such as diet, physical activity, and sleep patterns play a role on the development and management of both conditions, highlighting the need for integrated treatment strategies